These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 3321493)

  • 1. [Naftidrofuryl in the therapy of chronic arterial occlusive disease in the intermittent claudication stage].
    Valentin A; Karnik R; Stöllberger C; Slany J
    Vasa Suppl; 1987; 20():361-4. PubMed ID: 3321493
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical effectiveness of naftidrofuryl in intermittent claudication].
    Kriessmann A; Neiss A
    Vasa Suppl; 1988; 24():27-32. PubMed ID: 3062823
    [No Abstract]   [Full Text] [Related]  

  • 3. Naftidrofuryl for intermittent claudication: a double-blind controlled trial.
    Ruckley CV; Callam MJ; Ferrington CM; Prescott RJ
    Br Med J; 1978 Mar; 1(6113):622. PubMed ID: 343869
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of naftidrofuryl (Praxilene) on intermittent claudication.
    Waters KJ; Craxford AD; Chamberlain J
    Br J Surg; 1980 May; 67(5):349-51. PubMed ID: 6992910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of safety and efficacy of buflomedil and naftidrofuryl in the treatment of intermittent claudication.
    Rosas G; Cerdeyra C; Lucas MA; Parano JR; Villa JJ
    Angiology; 1981 May; 32(5):291-7. PubMed ID: 7235299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug therapy of intermittent claudication in the IIb stage of arterial occlusive disease].
    Kriessmann A; Neiss A; Lutilsky L; Beermann M; Kramann B
    Med Welt; 1979 Jun; 30(23):888-91. PubMed ID: 459805
    [No Abstract]   [Full Text] [Related]  

  • 7. A controlled trial of naftidrofuryl (Praxilene) in the treatment of intermittent claudication.
    Clyne CA; Galland RB; Fox MJ; Gustave R; Jantet GH; Jamieson CW
    Br J Surg; 1980 May; 67(5):347-8. PubMed ID: 6992909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness of Dusodril-Pi in arterial occlusive diseases. A multicentric double-blind study].
    Becker HM; Elert O; Häring R; Maurer PC; Raithel D; Sperling M; Stockmann U; Storz LW; Hirche H
    Med Welt; 1979 Oct; 30(43):1602-6. PubMed ID: 514039
    [No Abstract]   [Full Text] [Related]  

  • 9. [Naftidrofuryl in arterial occlusive disease. Controlled multicenter double-blind study with oral administration].
    Maass U; Amberger HG; Böhme H; Diehm C; Dimroth H; Heidrich H; Heinrich F; Hirche H; Mörl H; Müller-Bühl U
    Dtsch Med Wochenschr; 1984 May; 109(19):745-50. PubMed ID: 6373217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Double-blind study of naftidrofuryl-hydrogen oxalate in peripheral arterial occlusive disease].
    Pohle W; Hirche H; Barmeyer J; Schümichen C; Hoffmann G
    Med Welt; 1979 Feb; 30(7):269-72. PubMed ID: 372733
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of naftidrofuryl in patients with intermittent claudication.
    Karnik R; Valentin A; Stöllberger C; Slany J
    Angiology; 1988 Mar; 39(3 Pt 1):234-40. PubMed ID: 3281516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using Naftidrofuryl tablets 200 mg.
    Adhoute G; Bacourt F; Barral M; Cardon JM; Chevalier JM; Cuny A; Gillet M; Juhan C; Leguay G; Marion J
    Angiology; 1986 Mar; 37(3 Pt 1):160-7. PubMed ID: 3518547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intravenous naftidrofuryl on transcutaneous oxygen pressure in severe peripheral vascular disease.
    Taggart I; Wishart GC; Cuschieri RJ; MacBain GC
    Angiology; 1989 Oct; 40(10):895-8. PubMed ID: 2802260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Naftidrofuryl in stages III and IV of peripheral arterial occlusive disease].
    Horsch S
    Vasa Suppl; 1988; 24():38-43. PubMed ID: 3212602
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study.
    Adhoute G; Andreassian B; Boccalon H; Cloarec M; Di Maria G; Lefebvre O; Mondine P; Plagnol P; Pointel JP; Quancard X
    J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S75-80. PubMed ID: 1369725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Naftidrofuryl in patients with multi-infarct dementia and Alzheimer's disease].
    Grossmann W; Standl A; May U
    Vasa Suppl; 1988; 24():48-55. PubMed ID: 3212603
    [No Abstract]   [Full Text] [Related]  

  • 17. [Preliminary results of a long-term double-blind study of naftidrofuryl and a placebo in patients with moderate Alzheimer-type senile dementia].
    Cucinotta D; Dall'Asta D; Benaglia F; Barbagallo M; Butturini L; Pioli G; Salomone M
    G Clin Med; 1985; 66(11-12):467-76. PubMed ID: 3835091
    [No Abstract]   [Full Text] [Related]  

  • 18. [Naftidrofuryl in the treatment of simple diabetic retinopathy. A double-blind study].
    Klein M; Hirche H
    Klin Monbl Augenheilkd; 1985 Sep; 187(3):195-201. PubMed ID: 3906248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Training by walking and drug therapy of peripheral arterial occlusive disease].
    Kiesewetter H; Blume J; Jung F; Gerhards M; Leipnitz G
    Vasa Suppl; 1987; 20():384-7. PubMed ID: 3321495
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of naftidrofuryl on intermittent claudication: a meta-analysis.
    Lehert P; Riphagen FE; Gamand S
    J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S81-6. PubMed ID: 1369727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.